Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
Exonics Therapeutics, founded in 2016 and headquartered in Watertown, Massachusetts, is a biotechnology company at the forefront of gene editing technology. We specialize in developing innovative treatments for Duchenne muscular dystrophy using CRISPR/Cas9 technology. Our focus is on creating a potential one-time treatment that could permanently correct the mutation causing this debilitating condition.
Since its inception, Exonics Therapeutics has raised a total of $45 million in funding, demonstrating investor confidence in our pioneering approach to treating genetic disorders. Our use of cutting-edge CRISPR/Cas9 technology positions us as a potential leader in the field of gene editing therapeutics.
Regarding Exonics Therapeutics' IPO prospects, we currently have no concrete information or recent news to report. As a private company, any discussions about going public would typically be kept confidential until an official announcement is made. It's important to note that the decision to pursue an IPO depends on various factors, including market conditions, company readiness, and strategic objectives.
For investors interested in the biotechnology sector, particularly in companies working on gene editing technologies, it's advisable to keep an eye on Exonics Therapeutics' progress and any potential future announcements regarding its funding or public offering plans. However, as of now, there are no confirmed reports or rumors about Exonics Therapeutics' IPO prospects.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While Exonics Therapeutics' IPO prospects remain uncertain, investors eager to explore opportunities in the innovative gene therapy space don't have to wait. At Linqto, we offer members access to interests in promising private companies before they go public. Our platform provides the opportunity to invest in potential leaders in the biotechnology sector, like Exonics Therapeutics, with lower minimum investments than traditional private equity opportunities. This allows you to potentially benefit from the growth of cutting-edge companies in the gene therapy field before they hit the public markets.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
